BioNTech's Oncology Pivot Faces Its First Real Test in Madrid

BioNTech shares trade about 20% below their 52-week high as Morgan Stanley trims and Berenberg holds targets ahead of the ESMO congress.

BioNTech investors are approaching the company's next chapter with a mixture of anticipation and caution. With the pandemic-era revenue surge now firmly in the rearview mirror, the Mainz-based biotech's valuation increasingly rests on a single question: can its oncology pipeline deliver commercial results before the financial cushion from Covid-19 vaccines runs thin?

Two contrasting analyst notes this week capture the market's divided mood. Morgan Stanley's Terence Flynn trimmed his price target marginally to $114 from $115 while keeping an Overweight rating, citing shifting industry trends from IQVIA and interim updates ahead of third-quarter earnings. Berenberg's Luisa Hector, by contrast, left her target untouched at $140 and reiterated a Buy recommendation, pointing to the upcoming ESMO cancer congress as the key catalyst.

A Share Price Caught Between Two Narratives

The stock's recent trading reflects that tension. Shares changed hands at EUR 86.50 on Wednesday, up 1.6% on the day, though a separate reading earlier in the session showed EUR 85.00, down 0.2%. Either way, the current level sits roughly 20% below the 52-week high — a gap that underscores how much ground the company must recover to convince skeptics.

What unites both analyst camps is the conviction that scientific data, not quarterly financials, will determine the stock's direction from here. The ESMO congress, which opens in Madrid on October 23, has become the focal point for investors seeking proof that BioNTech's cancer therapy candidates can hold their own in a fiercely competitive field.

Restructuring Sets the Stage

The company's operational overhaul provides the backdrop to that scientific reckoning. More than a month ago, BioNTech confirmed it would gradually shut three German production sites — Tübingen, Marburg and Idar-Oberstein — after failing to find buyers. The decision, driven by a difficult market and investment environment, affects approximately 1,800 employees, with severance agreements already negotiated with the works council. Including a planned facility in Singapore, media reports suggest the cuts could touch around 1,860 positions.

Management has framed the retreat from pandemic-era manufacturing as a necessary streamlining, freeing capital for clinical research. Yet the move also strips away familiar tangible assets, leaving the pipeline as the company's primary source of value.

Founder Talks Add a Layer of Uncertainty

Complicating the picture are reported tensions surrounding the departure of founders Özlem Türeci and U?ur ?ahin. According to Handelsblatt, negotiations over their exit have grown difficult, with disagreements centering on patents, financial resources and personnel. Any escalation — particularly one that muddies the ownership of intellectual property — could inflict lasting damage on both reputation and substance. For a research-driven biotech, IP is the bedrock; legal wrangling over it tends to unsettle investors for extended periods.

Separately, regulatory filings with the SEC reveal that CEO U?ur ?ahin sold company shares in late September and early October. The transactions were executed under a trading plan established on June 3, 2026, in accordance with Rule 10b5-1 — a mechanism that pre-schedules sale timing and volumes, allowing executives to trade independently of current corporate developments.

What Lies Ahead

For now, the near-term trajectory hinges on two pillars. If the shares hold their current footing and no fresh complications emerge from the founder negotiations, the prospect of pipeline progress could tip sentiment toward stabilization. Should patent disputes escalate or clinical presentations fall short of expectations, however, a downward revaluation becomes a real risk.

The Madrid congress will be the decisive proving ground. Data unveiled there — and in the run-up to it — will tell investors whether BioNTech's transformation from vaccine maker to broad-based cancer specialist is genuinely on track, or whether the current valuation still needs recalibration.